RECEIVED CENTRAL FAX CENTER

JUN U 8 2007

Atty Docket No. 082368-007000US

PTO FAX NO.: 1-571-273-8300

ATTENTION:

Examiner

Group Art Unit

OFFICIAL COMMUNICATION FOR THE PERSONAL ATTENTION OF

EXAMINER

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following documents in re Application of Yasuo KUNUGIZA et al., Application No. 10/570,052, filed for GENE THERAPY FOR SKIN DISORDERS USING NEEDLELESS SYRINGES are being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

1. Status Request Letter

Number of pages being transmitted, including this page: 5

Dated: June 8, 2007

Sherbonné Barnes-Anderson Prosecution Paralegal Supervisor

PLEASE CONFIRM RECEIPT OF THIS PAPER BY RETURN FACSIMILE AT (415) 576-0300

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, CA 94111-3834 Telephone: 415-576-0200 Fax: 415-576-0300

0106

61072954 v1

CENTRAL FAX CENTER

JUN U 8 2007

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office. Fax No. 1-571-273-8300 on Jine 8, 2007

Docket No.: 082368-007000US Client Ref. No.: MED-A0402P-US

TOWNSEND and TOWNSEND and CREW LLP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Confirmation No.: 8162

Yasuo KUNUGIZA et al.

Examiner:

Int'l Appln. No.: PCT/JP04/12777

Art Unit:

Int'l Filing Date: August 27, 2004

STATUS REQUEST

U.S. Application No.: 10/570,052

LETTER

For: GENE THERAPY FOR SKIN DISORDERS USING NEEDLELESS

SYRINGES

June 7, 2007

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

As evidenced by the electronic filing acknowledgement returned to the undersigned bearing the Patent Office date stamp thercon (copy enclosed), the Missing Requirements in the subject application were received by the Patent Office on June 21, 2006.

To date, Applicant's attorney has not received a Notice of Acceptance from the Patent Office. Please advise us of the status of this application.

Respectfully submitted,

Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: (415) 576-0200 Fax: (415) 576-0300 KLB:sba61071207 v1

RECEIVED **Electronic Acknowledgement Receipt** CENTRAL FAX CENTER JUN U 8 2007 EFS ID: 1086535 **Application Number:** 10570052 **Confirmation Number:** 8162 Title of Invention: Gene therapy for skin disorders using needleless syringes First Named Inventor: Yaşuo Kunugiza **Customer Number:** 20350 Filer: Aaron Hokamura Filer Authorized By: **Attorney Docket Number:** 082368007000US Receipt Date: 21-JUN-2006 Filing Date: Time Stamp: 13:48:21 Application Type: U.S. National Stage under 35 USC 371 International Application Number:

Payment information:

Submitted with Payment	yes	
Payment was successfully received in RAM	\$ 5040	
RAM confirmation Number	823	
Deposit Account	201430	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17

Document Number	Document D _k ription	File Name	rile Size(Bytes)	Multi Part	Page:			
1	Oath or Declaration filed	Declaration.pdf	141796	nò	3			
Warnings:	· · · · · · · · · · · · · · · · · · ·	 *						
Information:		M						
2		Preliminary_Amendment.pdf	131316	yes	8			
	Multipart Description							
	Doc Desc		Start	End				
	Preliminary Amendment		1	1				
	Claims		2	7				
	Applicant Arguments/Remarks Made in an Amendment		8	8				
Warnings:								
Information:	APPROXIMATION OF THE PROPERTY		1					
3	Information Disclosure Statement (IDS) Filed	IDS.pdf	206036	no	3			
Warnings:				-				
Information:		#. 						
This is not an l	JSPTO supplied IDS fillable form	•						
4	Foreign Reference	JP2001500858A.pdf	1237174	nọ	39			
Warnings:	· · · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·		1			
Information:				· · · · · · · · · · · · · · · · · · ·				
5	Foreign Reference	JP2002542264A.pdf	1706441	no	55			
Warnings:			<u></u>		J			
Information:				•				
. 6	Foreign Reference	WO0200258A1.pdf	2734671	no	56			
Warnings:			<u> </u>					
Information:								
7	Foreign Reference	WO02066070A1.pdf	3390187	no	41			

PAGE 4/5 * RCVD AT 6/8/2007 4:56:30 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/12 * DNIS:2738300 * CSID:415 576 0300 * DURATION (mm-ss):00-48

1 % 0 4

Warnings:									
Information:									
8	Foreign Reference	WO02089854A1.pdf	3115319	nυ	57				
Warnings:									
Information:									
9	Foreign Reference	WQ9931262A2.pdf	<u> </u>	по	_. 37				
Warnings:									
Information		. , , ,							
10	Documents submitted with 371 Applications	International_Search_Report .pdf	141956	no	3				
Warnings:									
Information	•								
11	Transmittal letter	PCT_Transmittal.pdf	110755	no	3				
Warnings:									
Information									
12	Applicant Response to Pre-Exam Formalities Notice	Notification_of_MissIng_Req uirements.pdf	85251	no	2				
Warnings:		<u>-</u>							
Information									
13	Fee Worksheet (PTO-875)	fee-info.pdf	8525	no	2				
Warnings:									
Information:									
		Total Files Size (in bytes)	14	14609233					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the Indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.